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Abstract
The definition of the risk of hepatocellular carcinoma (HCC) recurrence after resection represents a central issue to improve
the clinical management of patients. In this study we examined the prognostic relevance of infiltrating immune cell subsets
in the tumor (TIL) and in nontumorous (NT) liver (LIL), and the expression of immune-related and lineage-specific mRNAs in
HCC and NT liver derived from 42 patients. The phenotype of infiltrating cells was analyzed by flow cytometry, and mRNA
expression in liver tissue was examined by real-time reverse transcription (RT)-PCR. The tumor immune microenvironment
was enriched in inhibitory and dysfunctional cell subsets. Enrichment in CD4+ T-cells and in particular CD4 and CD8+
memory subsets within TIL was predictive of better overall survival (OS) and time to recurrence (TTR). Increased
programmed death ligand 1 (PDL1) mRNA content and higher prevalence of invariant NKT (iNKT) cells were associated with
shorter OS and TTR, respectively. By combined evaluation of infiltrating cell subsets along with mRNA profiling of immune
and tumor related genes, we identified the intratumoral frequency of memory T-cells and iNKT-cells as well as PDL1
expression as the best predictors of clinical outcome. HCC infiltrate is characterized by the expression of molecules with
negative regulatory function that may favor tumor recurrence and poor survival.
Citation: Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, et al. (2012) Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for
Hepatocellular Carcinoma. PLoS ONE 7(3): e32493. doi:10.1371/journal.pone.0032493
Editor: Antonio Bertoletti, Singapore Institute for Clinical Sciences, Singapore
Received September 8, 2011; Accepted January 27, 2012; Published March 2, 2012
Copyright:  2012 Cariani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Italian Ministry of Health, Programma Straordinario Ricerca Oncologica 2006. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: missale@tin.it
Introduction
Hepatocellular carcinoma (HCC) is a fatal disease occurring
worldwide and developing mainly in patients with chronic liver
disease [1]. Surgical resection is an important therapeutic option
for small tumors, but the recurrence rate remains high and overall
survival of resected patients at 5 years is dismal. The recurrence of
HCC can be caused both by haematogenous dissemination of the
primary tumor, mainly within the liver itself, and by the
development of single or multiple de novo tumors arising in a
chronically damaged liver.
The clinical and histopathological characteristics of HCC can
only partially explain its prognostic heterogeneity. Several studies
have postulated the existence of two main determinants for the risk
of HCC recurrence: the molecular features of the tumor cells [2]
and those of the liver environment [3], [4].
Considerable effort has been devoted to the identification of
molecular profiles linked to HCC clinical features. Gene
expression studies allowed the identification of HCC subclasses
that share common molecular features and correlate with clinical
parameters [5], [6]. Several lines of evidence support the relevance
of hepatocyte differentiation [6], [7], [8], [9] and of immune
response genes [5], [10], [11], [12] in the molecular classification
of HCC, but the prognostic impact of the mRNA profile is still
controversial.
The potential role played by tumor- and liver-infiltrating
immune cells on the progression and recurrence of HCC is the
subject of ongoing studies. Tumor-infiltrating lymphocytes are
believed to inhibit tumor growth improving the prognosis of
human malignancies, but the secretion of cytokines by infiltrating
cells may also promote neovascularization and tumor dissemina-
tion [13], [14], [15].
The phenotypic characteristics of infiltrating immune cells
appear a major determinant for the clinical outcome in several
human tumors. Phenotyping of the intratumoral T-cells showed
that high levels of memory T-cells correlated with better survival
in colon cancer [16] and was associated with the expression of
genes involved in Th1 adaptive immunity [17]. In earlier studies
on HCC a T-cell infiltrate with predominance of CD8+ cells by
immunohistochemistry was associated with improved 5-year
survival rate [18]. More recently, the presence of lymphocyte
infiltration together with a higher CD4:CD8 T-cell ratio in HCC
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transplantation [19]. In addition, a shift from a Th1 to a Th2-like
profile has been postulated to occur in livers bearing metastatic
HCC [3].
Despite evidences supporting a role of infiltrating cells in the
surveillance of tumor progression, the poor prognosis of HCC
reflects the failure of effective immune control of neoplastic
growth. Cytotoxic T-cells (CTLs) infiltrating HCC show function-
al defects and incomplete activation associated with increased
programmed death 1 (PD1) expression [20], [21] that is predictive
of poorer disease outcome and postoperative recurrence [21].
Enriched programmed death ligand 1 (PDL1) expression was also
found in tumors [21], [22] and linked to HCC prognosis [22].
Another mechanism implicated in failure of immune control
against HCC progression is the suppression of effector cells by
regulatory T-cells (Tregs) [23]. Increased circulating and/or
intratumoral Tregs [22], [24], [25], [26], [27], as well as the
balance between intratumoral CTLs and Tregs [28] have been
associated with the outcome of HCC [29].
With the aim of a better comprehension of the characteristics of
the intrahepatic lymphocyte infiltrate in patients with HCC, its
possible role in disease outcome and its relation to histological and
molecular characteristics of the tumor, we conducted a phenotypic
analysis of tumor (TIL) and nontumorous (NT) liver (LIL)
infiltrating lymphocytes, together with genomic profiling of immune
related and lineage-specific mRNAs in HCC and NT liver.
Results
Characteristics of patients
The epidemiological, clinical and pathological characteristics of
patients are depicted in Table 1. HCC nodules were 1 to 5 in the
same patient and their size ranged from 30 to 50 mm in diameter. A
poorly differentiated tumor tissue was present in the majority of
patients.Noneofthepatientsshowedmacroscopicvascularinvasion.
The median overall survival (OS) was 84 months, while the
median time to recurrence (TTR) was 24 months (Fig. S1). Five
patients, deceased within 3 months from surgery, were only
included in the overall survival analysis but not in the prognostic
analysis of TTR and OS regarding all immunological and
molecular parameters.
Kaplan-Meier survival analysis of all epidemiological, clinical
and pathological characteristics listed in Table 1 showed
significantly longer OS for patients younger than 68 years and
for alcohol abusers. Shorter OS was associated with both hepatitis
C virus (HCV) infection, and female sex. However women of our
Table 1. Epidemiological, clinical and pathological characteristics of patients.
Univariate Multivariate
Variable Value TTR OS TTR OS
HR HR HR
(95%CI) p (95% CI) p p (95% CI) p
Age (#68 vs .68 years) 66.8168.84 0.70 0.45 0.31 0.03 NA NA 1.17 0.79
mean ± SD (0.27–1.78) (0.11–0.87) (0.34–3.97)
Gender (M/F) 31/11 0.61 0.36 0.09 ,0.001 NA NA 0.40 0.15
(0.21–1.76) (0.03–0.32) (0.11–1.42)
HBsAg pos (n) 4 1.31 0.7 0.5 0.32 NA NA NA NA
(0.34–5.06) (0.13–1.97)
Anti-HCV pos (n) 29 1.1 0.83 3.94 ,0.01 NA NA 3.82 0.25
(0.46–2.63) (1.45–10.73) (0.38–38.44)
Alcohol use (n) 11 0.87 0.74 0.29 0.02 NA NA 0.41 0.45
(0.37–2.05) (0.1–0.8) (0.04–4.19)
HCC (n=1 vs .1) 1 (1–5) 0.60 0.26 0.74 0.55 NA NA NA NA
median (range) (0.25–1.45) (0.27–2.03)
Nodules size (#50 vs .
50 mm) mean ± SD
57.62625.6 1.07 0.87 1.80 0.23 NA NA 0.55 0.29
(0.47–2.42) (0.70–4.6) (0.18–1.66)
Tumour grade (1–2 vs 3) 1.04 0.93 1.32 0.57 NA NA NA NA
median (range) 3 (1–3) (0.46–2.33) (0.50–3.46)
Microvascular
invasion pos (n)
25 1.45 0.37 1.51 0.43 NA NA NA NA
(0.64–3.28) (0.55–4.12)
TNM 1/2/3/4 (1 vs 2–4) 10/21/10/1 0.59 0.24 1.32 0.59 1.03 0.93 NA NA
(0.25–1.42) (0.46–3.79) (0.39–2.71)
Lymphomononuclear
infiltrate at histology (n)
7 0.49 0.15 0.43 0.2 0.42 0.18 0.31 0.27
(0.18–1.29) (0.12–1.54) (0.11–1.52) (0.04–2.47)
TTR: time to recurrence; OS: overall survival; HR: hazard ratio; CI: confidence intervals; NA: not applicable.
doi:10.1371/journal.pone.0032493.t001
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pected result. Multivariate analysis failed to identify any
independent parameter associated with TTR or OS (Table 1).
Differential distribution and clinical correlates of cell
subsets and mRNAs in HCC and nontumorous liver tissue
The distribution of cell subsets and of some of the analyzed
mRNAs was significantly different among HCC and nontumor-
ous liver tissues. HCC infiltrating cells were enriched in Tregs
(CD4+,C D 2 5 +,F o x P 3 +), PD1+/CD4+ or PD1+/CD8+ T-cells
and PD1+ Tregs. The frequency of the whole CD8+ T-cell
population within the total lymphocyte infiltrate was increased in
nontumorous liver tissue while CD4+ T-cells were more
represented in HCC tissue. Memory (CD127+/RA2)C D 4 +
and CD8+ T-cell subsets, granzyme B (GZB)+/CD4+ T-cells and
NKT-cells were all enriched in the NT liver tissue (Fig. 1A).
Figure 1. Differential distribution of infiltrating cell subsets and mRNAs between nontumorous and tumorous liver tissue samples.
A: infiltrating cell subsets B: mRNAs; white bars: nontumorous and grey bars: tumorous liver tissue samples. Significance levels are shown on top of
each panel. The right y axis of the upper panel refers to iNKT/CD3.
doi:10.1371/journal.pone.0032493.g001
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PD1/CD8 mRNA in HCC, the differences did not reach
statistical significance. mRNAs encoding cytokeratin 7 (CK7),
EpCAM, e-cadherin, arginase and interleukin 6 (IL6) were all
significantly more represented in NT liver tissue than in HCC
(Fig. 1B).
Among the histological characteristics of tumors, microvascular
invasion was accompanied by higher frequency of Tregs (CD25+
FoxP3+/CD3+,p ,0.05) and lower levels of e-cadherin (p,0.05)
mRNA expression in HCCs; higher tumor grade (=3) was
associated with higher expression of CD45 (p,0.05) and higher
frequency of Tregs (CD25+ FoxP3+/CD3+,p ,0.05) in HCC
when compared to lower grade; presence of histological lympho-
mononuclear infiltrate was detected in HCCs with higher alpha
fetoprotein (AFP) expression (p,0.05). The levels of transforming
growth factor ß1 (TGFß1) mRNA in tumorous tissue correlated
with expression of IL6 (p,0.001), vimentin (VIM) (p=0.01) and
PDL1 (p,0.05) (data not shown).
Tumor infiltrating lymphocyte subsets and mRNA
expression levels in the prediction of post-resection
outcome
Levels of mRNA expression and frequencies of lymphocyte
subsets in TIL and LIL were evaluated by Kaplan-Meier survival
curves for their association with TTR and OS. For each variable,
median levels were used as a cut-off value to analyze the
association with survival.
In the tumorous tissue, the frequency of CD3 and CD4+ cells
within the whole lymphocyte population were significantly
associated with longer TTR (Fig. 2). Furthermore CD4+/CD3+
cells were more represented in patients with better TTR and OS
(Figs. 2 and 3, respectively). An opposite association was shown for
CD8+/CD3+ cell subset, which was predictive of shorter TTR
and OS. Further phenotypic characterization, by staining for
CD127 and CD45RA, however showed that higher levels of
differentiation to a memory phenotype were associated with longer
TTR for CD8 (CD8+ CD127+RA2 cells). By contrast, a higher
Figure 2. Kaplan-Meier curves of time to recurrence (TTR) among HCC patients. Prognostic significance of the frequency of tumor (TIL) or
nontumorous liver infiltrating lymphocytes (LIL) are shown in the upper part of the figure. mRNA expression in nontumourus liver of IFN-c and
EpCAM is shown in the lower part of the figure. A specific cut-off (above or below 2.5-fold reference normal liver) was applied to EpCAM mRNA. TL:
total lymphocytes; low, high: lower or higher than median value. P values were determined by the log-rank test.
doi:10.1371/journal.pone.0032493.g002
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with shorter OS (Fig. 3).
Limiting the survival analysis to the anti-HCV positive patients,
the same trends were confirmed as in the whole population,
maintaining significant association with longer TTR for higher
frequency of CD8 CD127+RA2 cells in TIL (p,0.05; not
shown).
Among the remaining lymphocyte subsets represented in TIL,
only iNKT cells were significantly predictive of shorter TTR
(Fig. 2). Because of the limited amount of stored TIL, further
characterization of this lymphocyte subset could be performed in
only 5 patients, by staining iNKT-cells for CD4 and CD8 markers.
Most iNKT/CD3 cells were CD4+ (86.3614.3%), suggesting that
regulatory or Th2 iNKT-cells may be enriched in TIL of patients
with worse outcome. A prevalent CD4+ iNKT-cell phenotype was
also present in the peripheral blood compartment (67.7625.1) of
the same patients but frequencies of iNKT/CD3 and CD4+
iNKT-cells in the peripheral compartment were not significantly
associated with outcome (either TTR or OS) (data not shown). In
contrast to what observed within the tumor, patients with a higher
frequency of memory CD8+ T-cells in the nontumorous tissue had
a shorter TTR (Fig. 2).
Shorter TTR was observed when increased interferon c (IFN c)
and EpCAM (.2.5-fold) mRNAs were detected in NT (Fig. 2).
Higher PDL1 mRNA content in HCC, as well as CD8 and IFNc
mRNAs in NT liver higher than median levels were associated
with shorter OS (Fig. 3). The analysis of tissue sections by
immunohistochemical staining revealed that PDL-1 expression
was mainly expressed in tumor cells rather than in nonparench-
ymal cells (Fig. 4).
Discussion
Several lines of evidence suggest that the characteristics of both
tumor cells and infiltrating immune cells may represent major
determinants for the clinical outcome of HCC. Large-scale gene
expression studies have converged in the identification of three
major molecular profiles, characterized by high proliferation and
chromosomal instability, by activation of the Wnt signaling
pathway, and by IFN signalling due to tumor-infiltrating cells,
respectively [5], [6], [7], [8], [9], [10], [30], [31].
In most of previous reports, tumor and infiltrating cells have
been investigated independently and by different approaches:
infiltrating cell phenotype was evaluated in situ by immunohisto-
chemistry or on separated infiltrating cells by flow cytometry [18],
[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], whereas
Figure 3. Kaplan-Meier curves of overall survival (OS) among HCC patients. Prognostic significance of the frequency of tumor infiltrating
lymphocytes (TIL) are shown in the upper part of the figure. mRNA expression of PDL1 in tumor and of CD8 and IFN-c in nontumorous liver is shown
in the lower part of the figure. Low, high: lower or higher than median value. P values were determined by the log-rank test.
doi:10.1371/journal.pone.0032493.g003
Figure 4. PDL1 immunohistochemical staining. Four represen-
tative cases with high (A and B) and low (C and D) protein
expression are shown. PDL1 is mainly expressed by hepatoma cells
rather than infiltrating lymphomononuclear cells and stromal cell
elements.
doi:10.1371/journal.pone.0032493.g004
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RT-PCR [5], [6], [7], [8], [9], [10], [31]. In this study we used an
integrated approach including both phenotypic analysis of
infiltrating cells by flow cytometry and mRNA quantitation by
RT-PCR.
Our study shows, in agreement with previous reports [12], [20],
[21], [26], an important difference in the immune microenviron-
ment of HCC compared to nontumorous liver, since inhibitory
and dysfunctional cell subsets such as Tregs and PD1+ cells were
prevalent in the tumor. However the differential distribution of
CD8+, CD4+, FOXP3+, and PD1+ cell subsets between HCC
and nontumorous liver was not confirmed by mRNA quantitation.
Individual discrepancies between mRNA and protein levels might
be explained by cellular control mechanisms operating at
transcriptional and/or at translational level. In addition, the
overall mRNA amount is quantified regardless of the expressing
cell type(s), whereas phenotypic characterization detects the
abundance of a cell subset within the total infiltrating cell
population.
Previous studies showed that a better outcome of HCC can be
associated with the presence of lymphomononuclear infiltrate, low
circulating and/or intratumoral Tregs, and a positive balance
between intratumoral CTLs and Tregs [22], [24], [25], [26], [27],
[28], [29]. The lack of a significant association between Tregs
frequency and clinical outcome in our series may rely on the fact
that more advanced HCCs were included in previous studies
(TNM stage III and IV, Chinese anticancer association stage III,
Japanese general rules for primary liver cancer stage III and IV)
[24], [25], [26], [27], [28], that included cases with macrovascular
tumor thrombosis and distant metastasis that were not present in
our patients, with the exception of a single case presenting direct
infiltration of the transverse colon wall. Moreover frequency of
regulatory T cells within the tumor was significantly lower in
TNM 1 patients of our cohort (p,0.01, data not shown). Indeed,
an association between Tregs prevalence and HCC stage has been
reported [25], [26], [28]. In our series, tumors with microvascular
invasion were enriched in Tregs, in agreement with previous
reports [19], [28] and had lower expression of mRNA encoding e-
cadherin, an adhesion molecule frequently inactivated during the
cancer invasion process [32].
In our cohort a better representation of CD4 and CD8+
memory subsets was present in tumors with a more benign
outcome and was predictive of better overall survival and time to
recurrence, indirectly suggesting that effector CD4 and CD8+
cells, that were enriched in tumors with poor outcome, were likely
represented by dysfunctional T-cells.
Tumors with increased levels of AFP mRNA and high
histological grade were characterized by more abundant inflam-
matory infiltrate and the infiltrate of high-grade tumors was
enriched in Tregs. Consistent with these observations is the
probability that less differentiated (i.e. higher grade) HCCs elicit
the host immune response, possibly directed against differentia-
tion-related antigens, such as AFP, but that effectiveness of the
anti-tumor response is impaired by the high prevalence of Tregs
within infiltrating cells. The relative abundance of PD1+ cells
observed within the tumor infiltrate might contribute to the
inhibition of tumor-specific T-cells. In this context the correlation
between the expression of PDL1 and TGFß1 is suggestive of
synergic mechanisms of impaired tumor-specific T-cell response in
the same tumors.
Interestingly, in our study iNKT-cells were enriched in HCCs
with poor clinical outcome. CD4+ iNKT-cells are known to
provide a regulatory function by Th2 cytokine production and are
implicated in inhibiting expansion of tumor antigen-specific CD8+
T-cells. The CD4+ iNKT-cells have been found to be enriched in
intrahepatic malignant tumors [33] and could represent a new
target for immunotherapy. Thus, the prevalent CD4+ phenotype
of iNKT detected in our patients may contribute, along with
CD4+CD25+FoxP3+ cells, to create a negative intratumoral
microenvironment responsible for a dysfunctional CD8 cell
response.
A limited number of studies found a relationship between gene
expression profile of the tumor and survival outcome, reporting
poor prognosis in tumors with gene signatures related to cell
proliferation and to fetal-progenitor hepatic lineages [7], [8], [30].
In our analysis, only PDL1 among mRNAs expressed in HCCs
was associated significantly with poor outcome, in agreement with
previous observations of a tumor microenvironment favouring T-
cell dysfunction and apoptosis [20], [21], [22]. The gene
expression profile of nontumorous liver tissue has also been
implicated in the prognosis of HCC [3], [4], [31]. We identified
IFNc mRNA in NT tissue as predictor of both shorter TTR and
OS, while CD8/CD3 was only related to shorter OS. These
results suggest that an inflammatory liver microenvironment may
favor tumor recurrence, in agreement with recent results [4].
In conclusion, by a combined qualitative evaluation of
infiltrating T and NK cell subsets along with mRNA profiling of
immune and tumor related genes, we showed that intratumoral
enrichment of memory CD4 and CD8 T-cells may be predictive of
a better clinical outcome, while iNKT-cell frequency and PDL1
expression were associated with shorter time to recurrence and
overall survival, respectively. Comparison of lymphocyte subset
frequencies between liver and tumor provide evidence that HCC
are characterized by the expression of molecules with negative
regulatory function that may favor tumor recurrence and poor
survival.
Materials and Methods
Patients and samples
We evaluated 42 HCC patients that underwent liver surgery at
the University Hospital of Parma, Italy in the period 2001–2003.
These patients were diagnosed with HCC by ultrasonography,
computed tomography and magnetic resonance imaging in
selected cases. Four patients had been previously treated by
surgery and radiofrequency ablation, and underwent surgery
because of HCC recurrence. Liver function was assessed by the
Child-Pugh grading and all patients were within Child A scoring.
Serological markers of hepatitis B virus (HBV) and HCV were
performed for all patients as well as anti-human immunodeficiency
virus that was negative for all cases. All patients were treated and
received the same postoperative care by the same team of
surgeons, and had postoperative follow-up every three months for
the first 2 years, and every 6 months thereafter. The clinicopath-
ological features of the patients analyzed were age, gender,
number of tumor nodules, cumulative tumor size (sum of the main
nodules diameters), etiology of the liver disease, microvascular
venous infiltration, presence of lymphomononuclear infiltrate at
histology, cellular differentiation according to the Edmondson
classification (Table 1). The study was approved by the local
ethical committee (Comitato Etico Indipendente (IRB/IEC)
dell’Azienda Ospedaliera di Parma, Parma, Italy), and patients
gave written informed consent to participate in the study.
Biological samples
Liver and tumor specimens were collected in the operating
room. Nontumorous liver tissue was always derived from the same
liver segment of the HCC nodule with a free margin from the
Outcome Predictors after HCC Resection
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freshly derived, vitally frozen and stored in liquid nitrogen for later
analysis. For subsequent mRNA extraction and amplification
specimens were snap-frozen directly in the operating room.
Unfortunately, this was not possible for all specimens because of
logistics and the diagnostic needs of pathology; for this reason
paired analysis of infiltrating lymphocytes and mRNA expression
was available only for 13 subjects.
Isolation of liver and tumor infiltrating
lymphomononuclear cells (LIL, TIL)
Tissue samples of HCC and nontumorous liver were obtained at
surgeryand immediatelystoredinRPMIsolution.Forthe extraction
of lymphomononuclear infiltrate, contaminating blood was prompt-
ly removed by repeated washing with fresh RPMI using a syringe
and a 23 gauge needle. Tissues were then dissected into small
portions with a surgical blade, underwent a new step of RPMI
washing and finally were digested with collagenase (1 mg/ml) and
DNAse (25 mg/ml) (Sigma, St. Louis, MO, USA) for 1 h at 37uC.
Thereafter, tissue suspension was filtered with a cell strainer (70 mm)
(Becton Dickinson,CA, USA) and resuspended incomplete medium
(RPMI-1640 with 25 mM Hepes, 2 mM L-glutamine, 50 mg/ml
gentamycin and 10% heat-inactivated human serum). This
approach yielded 1–5610
6 infiltrating lymphomononuclear cells.
Phenotypic analysis of T and NK-cells in liver and tumor
compartments
For phenotypic characterization of lymphocyte populations,
cells were stained with monoclonal antibodies (MoAb) anti-PD1,
-forkhead/winged helix scurfy (FoxP3), -CD4, -GZB, -CD25,
-CD8, -CD127, -CD45RA, -CD3, -Va 24, -Vß11, -CD56.
Intracellular staining for FoxP3 and GZB was performed using
Fixation/Permeabilization reagents (e-Bioscience, San Diego, CA)
according to manufacturer’s protocol.
To assess the phenotypic and functional characteristics of
lymphocyte populations derived from the different districts, the
following panels of MoAb were used:
– Panel 1: anti-PD1/-FoxP3/-CD4/-GZB/-CD25/-CD8 for
Tregs identification, GZB content and PD1 expression on T
and Tregs.
– Panel 2: anti-PD1/-CD4/-CD127/-CD45RA/-CD3/-CD8
for characterization of memory and effector T-lymphocytes.
– Panel 3: anti-Va 24/-Vß11/-CD3/-CD56/-CD8/-CD4 for
NK and NKT subsets.
RNA extraction, cDNA synthesis and quantitative analysis
of selected mRNAs by RT-PCR
Tissue specimens for subsequent RNA extraction were snap-
frozeninliquid nitrogen just afterresection.TotalRNAwasisolated
from tumors and surrounding tissue by Trizol reagent (Invitrogen,
Carlsbad, CA) or RNAeasy Mini-kit (Qiagen, Hilden, Germany).
Random-primed cDNA first strand was synthesized by Superscript
VILO (Invitrogen) and amplified in duplicate by TaqMan Gene-
Expression Assays and Taqman Gene-Expression Master Mix
(Applied Biosystems, Foster City, CA) on a Rotor Gene 3000
(Corbett Research, Sydney, Australia). Each sample was amplified
in duplex with the internal reference human hypoxanthine-guanine
phosphorybosyl transferase (HPRT1) using Human HPRT1 MGB
Taqman assay (Applied Biosystems). Amplification efficiency of
individual reactions, calculated by the Rotor Gene software, was
automatically used as a correction factor for results and allowed the
exclusion from analysis of reactions showing low efficiency.
A relative quantitation approach was applied by comparing the
level of target gene expression between a sample and a reference
material, i.e. normal donor peripheral blood mononuclear cells for
immune response-related genes, or normal liver RNA (Ambion
Corp., The Woodlands, TX) for lineage-related genes. The
endogenous control HPRT1 was used to normalize input RNA
amounts. Targets for the quantitation of gene expression were
selected among molecular biomarkers potentially related to HCC
prognosis [3–12] and included differentiation-related mRNAs
expressed by fetal/progenitor liver cells, as insulin-like growth
factor 2 (IGF2), AFP, EpCAM, CK7, VIM; genes potentially
involved in HCC growth and invasiveness as e-cadherin, an
adhesion molecule, and arginase. In addition, genes involved in
adaptive and innate immune response as CD8, GZB, IFNc, IL6,
FoxP3, PD1, PDL1 and TGFß1 were also examined.
The results (target levels normalized to endogenous control
levels) were expressed as a fold-change or a fold-difference
compared to the reference tissue. mRNA level of immune
response genes was further normalized to mRNA encoding
CD3, CD4 or CD8 as appropriate. Since PDL1 is expressed both
by infiltrating and in nonimmune cells, its mRNA was included in
the analysis with or without prior normalization to CD45,
considered as representative of the total liver infiltrate.
Immunohistochemistry
Immunohistochemical staining of formalin fixed, paraffin-embed-
ded tissue sections was performed on 15 HCC samples. The rabbit
polyclonal Anti-CD274 (Abcam, Cambridge, MA), 5 mg/ml, was
used as primary antibody. Heat-mediated antigen retrieval was
performed with sodium citrate buffer (pH6) for 20 minutes; incu-
bation was at room temperature for 15 minutes. Slides were deve-
loped with a horseradish peroxidase-conjugated compact polymer
system (Advance HRP Kit, Dako) using diaminobenzidine as
chromogen and counterstained with haematoxylin. Negative controls
consisted of substituting normal serum for the primary antibody.
Statistical analysis
Statistical analysis was performed by Graph-Pad Prism 5.04
Software. The differences between groups of continuous variables
were analyzed by Mann-Whitney test or Wilcoxon matched pairs
test, as appropriate, whereas categorical variables were compared
by Fisher’s exact test. Correlation was analyzed by the Spearman
correlation coefficient. Survival curves were estimated by the
Kaplan-Meier method and compared by log-rank test. Cox
regression technique was performed for multivariate analysis. For
the selection of variables to be included in the multivariate model
we chose variables presenting p,0.25 at the univariate analysis. A
p value,0.05 (two-tailed) was considered significant.
Supporting Information
Figure S1 Percent survival of the whole study popula-
tion after surgery. OS: overall survival; TTR: time to
recurrence.
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